Login
Home / MAPT : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Maptelligent, Inc.

$0 -$0.00 (-33.33%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0
Year Range
$0$0
Market Cap
158.53K
AVG Volume
15.05K
Trailing/Forward PE
0.04/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD) · TTM
00.250.50.75121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Net Income (USD) · TTM
-50M050M100M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Operating Income (USD) · TTM
-3M-2M-1M021 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
EBITDA (USD) · TTM
-50M050M100M21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Cash Flows (USD) · TTM
-1.5M-1M-500K021 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
EPS (USD) · TTM
-100-75-50-2502521 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Expenses (USD) · TTM
01M2M3MSG&ACapex21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Shares Outstanding · TTM
-1M-750K-500K-250K0250K21 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q223 Q3
Employee Count
05001K1.5K201720182019202020212022
PE Ratio
00.20.40.60.8med 0.52Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Free Cash Flow Yield
-60000%-40000%-20000%0%med -162.02%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EV/EBITDA
0.60.70.80.911.1med 0.98Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Maptelligent, Inc.
MAPT
Stockpicker

Video analysis: MAPT

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: MAPT

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

gurufocus.com · 14 Jul 2026

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.